Avecho Biotechnology Limited (ASX:AVE)

Australia flag Australia · Delayed Price · Currency is AUD
0.0100
+0.0010 (11.11%)
At close: Mar 4, 2026
Market Cap33.06M +108.6%
Revenue (ttm)1.24M +9.3%
Net Income-4.42M
EPS-0.00
Shares Out3.67B
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume3,783,999
Average Volume6,138,866
Open0.0100
Previous Close0.0090
Day's Range0.0090 - 0.0100
52-Week Range0.0030 - 0.0110
Beta0.96
RSI46.81
Earnings DateFeb 26, 2026

About Avecho Biotechnology

Avecho Biotechnology Limited, a biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, the Americas, and India. It operates through Production and Human Health segments. The company manufactures and sells TPM and Vital ET products for use in drug delivery. Its human health portfolio covers delivery of pharmaceutical products for pain and dermatology applications through gels, injectables, and patches. In additio... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1992
Employees 15
Stock Exchange Australian Securities Exchange
Ticker Symbol AVE
Full Company Profile

Financial Performance

In 2025, Avecho Biotechnology's revenue was 1.24 million, an increase of 9.28% compared to the previous year's 1.13 million. Losses were -4.42 million, 41.5% more than in 2024.

Financial Statements